Pharma companies under Choice Institutional Equities' coverage delivered a strong performance during the recent quarter, with average year-on-year (YoY) revenue rising by 12.8 per cent.
With the US generics facing a challenge, Nuvama Institutional Equities on Tuesday said it prefers domestic formulations and CDMO names. Its top picks included Ajanta Pharma, Torrent Pharma, Divi’s ...
Hosted on MSN
Divis Lab gains as broker reiterates buy call
Mumbai, Aug. 22 -- The brokerage downplayed concerns over Eli Lilly's oral GLP-1 candidate Orforglipron and generic risks to Novartis' heart drug Entresto, which contributes about 20% of Divi's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results